VNRX · Volitionrx Ltd · Financials
Substantial doubt about the company's ability to continue as a going concern.
“The Company concluded that these plans do not alleviate the substantial doubt about the Company's ability to continue as a going concern within one year from the date the condensed consolidated financial statements are issued.”View the 10-Q filed Aug 13, 2026
2 customers — 38% of receivables (At December 31, 2025)
“At December 31, 2025 the two largest customer balances represented over 38% of the total outstanding accounts receivable balance.”
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $2.46M | $1.73M | $1.23M | $775.3K | $306.39K | $90.04K | $13.43K | $17.1K | — | — | — | — | $14.79K | — | $54.97K | $0 | |
| $9.41M | $10.08M | $14.41M | $19.55M | $15.33M | $13.02M | $14.53M | $10.36M | $10.91M | $8.03M | $7.9M | $6.1M | $4.04M | $2.5M | $2.77M | $1.52M | |
| $3.36M | $3.92M | $5.36M | $6.84M | $6.58M | $3.72M | $1.07M | $965.71K | $1.17M | $836.47K | $347.71K | — | — | — | — | — | |
| $9.11M | $9.46M | $8.49M | $10.37M | $10.18M | $11.68M | $5.65M | $4.73M | $5.82M | $5.83M | $4.18M | $669.02K | $299.05K | $434.01K | $448.04K | $247.41K | |
| — | $24.01K | $0 | $84.91K | $75.56K | $91.65K | $88.63K | $87.29K | $91.91K | $87.99K | $86.46K | $85.9K | $95.04K | $114.88K | $112.06K | $107.64K | |
| $874.46K | $983.71K | $1.11M | $1.15M | $936.08K | $945.37K | $716.18K | $676.82K | $636.38K | $528.17K | $309.41K | $236.34K | $142.13K | $146.4K | $135.74K | $118.62K | |
| $21.88M | $23.47M | $28.26M | $36.76M | $32.09M | $28.42M | $21.26M | $16.06M | $17.9M | $14.7M | $12.43M | $10.01M | $5.95M | $4.58M | $4.14M | $2.61M | |
| -$19.42M | -$21.74M | -$27.02M | -$35.99M | -$31.78M | -$28.33M | -$21.25M | -$16.04M | -$17.9M | -$14.7M | -$12.43M | -$10.01M | -$5.95M | -$4.58M | -$4.08M | -$2.61M | |
| — | -1258.47% | -2190.9% | -4641.76% | -10372.36% | -31468.96% | -158176.25% | -93840.22% | — | — | — | — | -40258.37% | — | -7428.05% | — | |
| -$18.55M | -$20.75M | -$25.91M | -$34.84M | -$30.84M | -$27.39M | -$20.53M | -$15.37M | -$17.26M | -$14.17M | -$12.12M | -$9.77M | -$5.81M | -$4.43M | -$3.95M | -$2.49M | |
| — | — | — | — | — | $155.8K | $129.8K | $126.57K | -$110.92K | $73.13K | $20.38K | — | — | — | — | — | |
| -$6.31M | -$1.76M | -$233.02K | $310.62K | $1.18M | $1.34M | $848.52K | -$56.13K | -$110.92K | — | — | -$15.68K | $14.79K | — | — | — | |
| — | — | — | — | — | — | — | — | — | — | — | -$4604 | — | — | — | — | |
| -$25.59M | -$23.36M | -$26.97M | -$35.68M | -$30.6M | -$26.99M | -$20.4M | -$16.1M | -$18.01M | -$14.77M | -$11.91M | -$9.53M | -$8.21M | -$3.71M | -$4.08M | -$2.61M | |
| — | -1352.16% | -2186.27% | -4601.7% | -9986.71% | -29976.99% | -151859.55% | -94168.55% | — | — | — | — | -55553.12% | — | -7428.05% | — | |
| — | — | -$290.15K | -$358K | $329.68K | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | -$26.97M | -$35.32M | — | — | — | — | — | — | — | — | — | — | — | — | |
| -$25.38M | -$24.18M | -$27.12M | -$35.66M | -$30.52M | — | — | — | -$17.66M | -$14.71M | -$12.01M | -$9.51M | -$8.26M | -$3.74M | -$4.12M | -$2.57M | |
| USD/shares | — | — | -$6.20 | -$10.00 | — | — | — | — | — | — | — | — | — | — | — | — |
| shares | — | — | — | — | — | 2.63M | 2.26M | 1.96M | 1.57M | 1.32M | 1.15M | 886.59K | 671.76K | 541.62K | 468K | — |
| shares | — | 5.34M | 4.33M | 3.56M | — | 2.63M | 2.26M | 1.96M | 1.57M | 1.32M | 1.15M | 886.59K | 671.76K | 541.62K | 468K | — |
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2022–FY2024: $31.77K in buybacks.
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Current finance lease liabilities | 2026-06-30 | USD 53,593 | 10-Q filed 2026-08-13 |
| Current operating lease liabilities | 2026-06-30 | USD 204,724 | 10-Q filed 2026-08-13 |
| Long-term debt, including current maturities | 2026-06-30 | USD 7,051,835 | 10-Q filed 2026-08-13 |
Related accounting measures — not additional borrowingCarrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.
| |||
| Noncurrent finance lease liabilities | 2026-06-30 | USD 282,278 | 10-Q filed 2026-08-13 |
| Noncurrent operating lease liabilities | 2026-06-30 | USD 157,478 | 10-Q filed 2026-08-13 |
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 47 similar-size Medical Devices companies (of 155 listed).